Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

NxTag respiratory panel v2 gets FDA clearance

July 2024—Diasorin received FDA 510(k) clearance for its NxTag Respiratory Pathogen Panel v2. The updated panel adds SARS-CoV-2 to its mix of 19 viral and two bacterial targets. The updated kit provides enhanced target performance to increase inclusivity and specificity, while improving usability of the product with easier-to-identify plate seals, according to a company press statement. The panel runs on the Magpix system, which tests up to 96 specimens in a single run.

Agilent unveils NovoCyte Opteon spectral flow cytometer

July 2024—Agilent Technologies unveiled its Novo­Cyte Opteon spectral flow cytometer in May at Cyto 2024, the 37th annual congress of the International Society for Advancement of Cytometry, in Edinburgh, Scotland. The system acquires, analyzes, and reports flow data across diverse domains, from basic research to drug discovery and therapy development. It features a user-friendly design and configurations ranging from three to five lasers and up to 73 high-quality detectors. Advanced engineering with proprietary technology ensures optimized light collection and electronic signal collection, real-time monitoring, and reliable data acquisition.

FDA clears QIAstat-Dx respiratory syndromic testing panel

July 2024—Qiagen announced that the FDA has cleared its QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. The panel, which was previously authorized for emergency use as the QIAstat-Dx Respiratory SARS-CoV-2 panel, covers 21 viral and bacterial targets. Hands-on time is less than one minute and results are provided in about an hour on the QIAstat-Dx analyzer. The company says it is working on expanding its portfolio for the QIAstat-Dx with a gastrointestinal panel, under FDA review, and a meningitis/encephalitis panel.

Roche gets breakthrough device designation for Lp(a) assay

July 2024—Roche announced that the Tina-quant lipoprotein Lp(a) RxDx assay, developed in collaboration with Amgen, has received breakthrough device designation from the FDA. The assay measures lipoprotein (a) in a person’s bloodstream and is for use in identifying patients who may benefit from Lp(a)-lowering therapy now in development. If approved, the assay will be available on select Cobas platforms.

OGT launches SureSeq Myeloid Fusion panel

July 2024—OGT has launched the RNA-based SureSeq Myeloid Fusion panel, a next-generation sequencing tool for identifying key fusion genes implicated in acute myeloid leukemia. The panel identifies more than 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. It is fully compatible with OGT’s Universal NGS Complete Workflow Solution and complimentary data analysis software, Interpret.

Mayo Clinic Labs, Progentec launch lupus biomarker testing services

July 2024—Progentec Diagnostics proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available. The AiSLE DX lupus disease activity index and AiSLE DX lupus flare risk index tests are the result of a collaboration with Mayo Clinic Laboratories and are now accessible to all clients of Mayo Clinic Labs.

FDA clears TEG 6s Global Hemostasis-HN cartridge

July 2024—Haemonetics Corp. has received FDA 510(k) clearance for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. The cartridge extends the TEG 6s’ viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries and procedures and liver transplantation in laboratory and point-of-care settings.

FDA clears Leica Biosystems Aperio GT 450 DX

June 2024—Leica Biosystems announced that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the U.S. Food and Drug Administration. The Aperio GT 450 DX is proven technology that offers both SVS and Native DICOM and consistently delivers high-quality images at a turnaround time of less than 32 seconds per slide.

Next-gen StatStrip glucose system gets 510(k) clearance

June 2024—Nova Biomedical announced the U.S. launch of its 510(k)-cleared, next-generation StatStrip glucose hospital meter system. New features include a Linux operating system with enhanced cybersecurity, RFID data entry, wireless charging, and a hematocrit range of five to 75 percent. The meter is FDA cleared for testing patients who are critically ill.

HemoSonics gets special clearance for QStat cartridge

June 2024—HemoSonics received special 510(k) clearance from the FDA for the expanded use of arterial blood samples with its Quantra QStat cartridge. The QStat cartridge used with the Quantra hemostasis analyzer first received 510(k) clearance in 2022 for use in venous whole blood samples.

MARKETPLACE

TRENDING